LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Quick and Accurate COVID-19 Test Identifies Neutralizing Antibodies to Aid Vaccine Immunity Monitoring

By LabMedica International staff writers
Posted on 06 Jan 2021
Print article
Illustration
Illustration
Researchers have developed a new technology to aid COVID-19 vaccine immunity monitoring with potential for use as an in-home antibody test.

As the COVID-19 vaccine becomes available to the public, immunity monitoring will play an important role in determining whether the vaccine is effective for an individual, and for how long. A new diagnostic test developed by researchers at the University of Alabama (Birmingham, AL, USA) is an accurate and reliable method for determining whether individuals are protected against COVID-19. The technology identifies neutralizing antibodies - those that block the virus from infecting cells. Emerging research suggests neutralizing antibodies offer the best protection against the virus.

The most widely used antibody tests today do not specifically identify neutralizing antibodies. Currently, these neutralizing antibodies can only be measured at a high level of accuracy using complicated and time-consuming laboratory tests not available to the general public. Existing antibody tests use a broad approach to locating antibodies, which attach to very small and distinct pieces of the virus. Current tests can mistake antibodies for other viruses, such as the common cold, for COVID-19 antibodies, leading to possible false-positive results.

To create the new test, the researchers began breaking down the COVID-19 virus into small pieces to identify the exact locations where antibodies attached to the virus. The results were better than the researchers anticipated, with the test detecting 20% more positive cases than the current gold-standard clinical antibody test. The ability to specifically recognize even small amounts of antibodies accurately is an important achievement, according to the researchers.

Immunity to COVID-19 is not anticipated to last forever, and immunity monitoring could continue for several years, even after widespread administration of a vaccine. Clinical trials indicated that COVID-19 vaccines may be remarkably successful; however, even 95% effectiveness will leave millions unprotected. Antibody testing helps determine efficacy and should help indicate whether a person is protected against the virus. The researchers hope to transition the technology to an inexpensive and easy-to-use test that will provide in-home immunity monitoring for the general public.

“The goal of every vaccine is to get the body to produce antibodies, which serve as a first line of defense against the virus,” said Benjamin Larimer, Ph.D., researcher at the University of Alabama at Birmingham, who developed the test. “Tests that specifically detect these antibodies can be used to measure whether a vaccine works, and possibly predict how long its protection will last.”

Related Links:
University of Alabama

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.